COVID-19 treatment prevention
Home » COVID-19 Resources

COVID-19 Resources

SynBioBeta is proud to partner with Leaps by Bayer to make a visual timeline for COVID-19 treatment and prevention. The scientific community is working around the clock, not only to protect us from COVID-19, but to prevent future strains from causing disruption and chaos.

We invite you to share this infographic with friends, family, and peers in your digital community, to bring much needed awareness to the synthetic biology solutions being developed, as well as the underlying science employed in developing both preventative measures and future treatments.

#FromTreatmentToPrevention #ShareTheScience

SynBioBeta and Leaps by Bayer COVID-19 Infographic

If you’d like to adapt this infographic for your own use or publication then please contact info@synbiobeta.com. Our data is sourced from the Milken Institute’s COVID-19 Tracker: https://milkeninstitute.org/covid-19-tracker. Accurate as of March 24, 2020.

Download Infographic

Download Mobile Infographic

“Leaps by Bayer is excited to partner with SynBioBeta on this visual timeline to show humanity that there is hope towards many of these therapies for treatment and prevention of COVID-19”, said Juergen Eckhardt, SVP and Head of Leaps.

Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of today’s biggest challenges in health and agriculture. The investment portfolio includes more than 30 companies working on potentially breakthrough technologies including BlueRock Therapeutics (Regenerate lost tissue function), Joyn Bio (Reduce environmental impact of farming) as well as Khloris, Century Therapeutics and Pyxis Oncology (Prevent and cure cancer). For more information, go to www.leaps.bayer.com


A series of online events, hosted by John Cumbers, providing updates from some of the front-line thinkers and doers tackling the technical and social challenges to address the global pandemic.

John Cumbers
John Cumbers, CEO/Founder – SynBioBeta

SynBioBeta resources for synthetic biology response to coronavirus

COVID-19 resources for synthetic biology response to coronavirus. Thank you to Megan Palmer and Connor Hoffman of the Center for International Security and Cooperation (CISAC) at Stanford University for compiling these resources.

World Health Organization

The WHO maintains a site with comprehensive information and guidance on the global emergency response effort to the COVID-19 outbreak. Covered topics include guidances on personal protection and travel, regularly published situation reports, and information global research activity; they have provided additional technical guidances on critical preparedness, readiness, and response, particularly in responding to community spread of COVID-19. 

Milken Institute

The Milken Institute is currently tracking the development of treatments and vaccines for COVID-19 (coronavirus).

American Biological Safety Association

ABSA International also maintains an information page on COVID-19 with information on coronaviruses, symptoms of COVID-19 and its transmission. More substantive information can be found in their SARS-Cov-2/COVID-19 Toolbox, including epidemiology and sequence data, information on training, regulatory resources, workplace practices, community resources, as well as access points for recent research publications relevant to SARS-Cov-2.

US Centers for Disease Control and Prevention

CDC maintains an index page for information on COVID-19, with directories for risk, transmission, symptoms, and treatment, as well as regular updates on the outbreaks globally. There are guidances for communities, healthcare workers/departments, and for domestic/international travel. Specific guidance on preparing communities for the spread of COVID-19 is also available.

Johns Hopkins University

Johns Hopkins University & Medicine has an institutional depth in the field of global health, and has produced a wealth of material targeted toward healthcare systems and their efforts to prepare for the spread of COVID-19. They also maintain a COVID-19 dashboard which tracks in real time the scope of the outbreak globally.

Funding:

HR 6074 provides $8.3B emergency appropriations to address COVID-19. HHS will direct funding to FDA, CDC, NIH, and the Public Health and Social Services Emergency Fund to address COVID-19 testing and outbreaks in the US. Additionally, emergency appropriations will be directed to the Small Business Administration, DoS, and USAID to help address outbreaks internationally. The funding is intended to aid in:
  • developing, manufacturing, and procuring vaccines and other medical supplies;
  • grants for state, local, and tribal public health agencies and organizations;
  • loans for affected small businesses;
  • evacuations and emergency preparedness activities at U.S. embassies and other State Department facilities; and
  • humanitarian assistance and support for health systems in the affected countries

Nuclear Threat Initiative

The Nuclear threat initiative Biosecurity program has produced recommendations for addressing the COVID-19 outbreak in partnership with the Center for Global Development. They have specifically called for leadership by the US government to take on this challenge globally. Contrast the scope of their concept Global Health Security Challenge Fund with what is being offered by the US Congress.

Other government resources

Share the Science

#COVID19
#FromTreatmentToPrevention #ShareTheScience